https://peptos.life/fda-tracker/news A dated, sourced changelog of the peptide regulatory landscape — PCAC, GLP-1/503B, RFK-14 reclassification, and enforcement. Primary FDA sources only. Compounded medications are not FDA-approved. en-us Tue, 16 Jun 2026 00:00:00 GMT 1440 https://peptos.life/fda-tracker/news/fda-pcac-july-2026-peptide-vote pcac-july-scheduled PCAC Wed, 10 Jun 2026 00:00:00 GMT The FDA's Pharmacy Compounding Advisory Committee will review seven peptides on July 23–24, 2026. The vote is advisory: a favorable recommendation leads to rulemaking, not instant availability. We'll publish the outcome the same day. https://peptos.life/fda-tracker/news/glp1-503b-exclusion-comments-close-june-29 glp1-503b-comment-window GLP-1 / 503B Wed, 20 May 2026 00:00:00 GMT The FDA has proposed excluding semaglutide, tirzepatide and liraglutide from 503B bulk compounding. Public comments close June 29, 2026. The approved branded products remain available; the proposal targets compounded supply. https://peptos.life/fda-tracker/news/category-2-removal-is-not-authorization cat2-removal-honest-read Peptide reclassification (RFK-14) Sat, 02 May 2026 00:00:00 GMT Some are reading the April 2026 removal of peptides from compounding Category 2 as a green light. The more authoritative legal reading does not: removal is not the same as Category 1, the Bulks List, or availability. The verdict dot stays amber. https://peptos.life/fda-tracker/news/what-the-rfk-14-peptide-reclassification-means rfk14-reclassification-explainer Peptide reclassification (RFK-14) Wed, 22 Apr 2026 00:00:00 GMT “RFK-14” is shorthand for the group of peptides swept into the 2026 compounding-policy review. Reclassification changes how — and whether — a licensed pharmacy may compound them. It is a regulatory mechanism, not a clinical endorsement.